Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Good morning ladies and gentlemen, and welcome to Companhia ...
First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback